X
Xin Wang
Researcher at Peking University
Publications - 1043
Citations - 30114
Xin Wang is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 59, co-authored 762 publications receiving 22731 citations. Previous affiliations of Xin Wang include Beihang University & Sichuan University.
Papers
More filters
Journal ArticleDOI
NAT10 Promotes Tumorigenesis of Diffuse Large B-Cell Lymphoma By ac4C-Dependent Acetylation of SLC30A9
TL;DR: In this paper , the role of NAT10 modification in diffuse large B-cell lymphoma (DLBCL) remains unclear, and the functional significance and regulatory mechanism of NAT 10-mediated mRNA ac4C modification in the tumorigenesis of DLBCL, which is expected to propose novel therapeutic strategy.
Journal ArticleDOI
Investigating the Hydroxyl Reorientation in Hydroxyapatite Using Machine Learning Potentials
Jing Wang,Xin Wang,Dingguo Xu +2 more
TL;DR: In this paper , the authors developed a machine learning atomistic potential for HAP using an active learning algorithm, which achieved density functional theory-level accuracy in describing hydroxyl groups in HAP.
Journal ArticleDOI
Design, Synthesis, and Bioevaluation of a Novel Hybrid Molecular Pyrrolobenzodiazepine-Anthracenecarboxyimide as a Payload for Antibody-Drug Conjugate.
Weirong Lai,Shengya Zhao,Qinhuai Lai,Wei Zhou,Meng-Ling Wu,Xiaohua Jiang,Xin Wang,Yujia Peng,Xian Wei,Liang Ouyang,Lantu Gou,Hao Chen,Yuxi Wang,Jinliang Yang +13 more
TL;DR: It is demonstrated that T-PBA could be degraded through the lysosomal pathway to release the payload 37b3 after internalization, which showed a powerful killing effect on Her2-positive cancer cells in vitro.
Journal ArticleDOI
Tumor Heterogeneity-Based Sscr-Score Predicts Prognosis and Reveals Mechanism of SORL1 in Restraining CLL Progression
TL;DR: In this paper , a prognostic model associated with CLL cell differentiation status was established to refine the risk assessment of CLL patients by identifying genes different expressed between aggressive and indolent subsets.
Journal ArticleDOI
Surgical outcomes and patient-reported outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy.
TL;DR: In this article , a consecutive series of unresectable stage III NSCLC patients were collected to investigate the surgical outcome and postoperative symptom changes in locally advanced patients who received adjuvant chemotherapy combined with immunotherapy.